ASCO 2017

A Novel Risk Score to Identify Insignificant Prostate Cancer in Unscreened Patients

Chicago—Management of patients with insignificant prostate cancer is increasingly utilizing active surveillance, and risk scores that use pre-operative factors have been developed. Lorenzo Dutto, MD, and colleagues recently evaluated the accuracy of nine separate tools developed to identify patients harboring insignificant prostate cancer. The assessment was conducted in a cohort of 2613 patients who underwent radical prostatectomy for Gleason score ... Read More »

ACDC-RP Trial Underway in Canada

Chicago—Based on recent advances in the management of de novo hormone-sensitive prostate cancer with both docetaxel and abiraterone, and on the evidence of significant activity of cabazitaxel in the post-abiraterone castrate-resistant setting, Anthony M. Joshua, MD and colleagues hypothesized that the addition of cabazitaxel to neoadjuvant abiraterone would improve pathological complete response rates by overcoming mechanisms of resistance in localized ... Read More »

Increased Risk of Dementia with Androgen Deprivation Therapy Possible

Chicago—There may be an increased risk of dementia in men with prostate cancer who are treated with androgen deprivation therapy (ADT); however, data from previous studies have shown conflicting results. Kevin Thomas Nead, MD, and colleagues recently conducted a systematic review and meta-analysis to determine the association of prostate cancer treatment with ADT and the risk of dementia. The researchers ... Read More »

Multi-Modal Approach to Treat High-Risk Prostate Cancer Safe and Effective

Chicago—During a poster session at the 2017 ASCO Annual Meeting, Stephanie Rice, MD, and colleagues reported long-term results of a prospective, phase II study of 2 years of androgen deprivation therapy (ADT), 45 Gy bone marrow sparing pelvic radiation, Cs-131 brachytherapy boost (85 Gy), and four cycles of adjuvant docetaxel (75 mg/m2 every 21 days plus prednisone) in high-risk, localized ... Read More »

Identification of Patients Sensitive to Chemotherapy

Chicago—Loss of the retinoblastoma tumor suppressor function has been identified as a major factor in the development of castrate-resistant prostate cancer (CRPC). The expression of the androgen receptor is under stringent retinoblastoma control, and tumors that are devoid of retinoblastoma function are hypersensitive to chemotherapy treatment. Based on exploratory analyses to evaluate baseline N-terminal androgen receptor expression in circulating tumor ... Read More »

PSA Screening History and Severity of Prostate Cancer at Diagnosis

Chicago—In 2012, the US Preventive Services Task Force gave the use of prostate-specific antigen (PSA) screening to detect prostate cancer a Grade D recommendation. Studies conducted recently in the United States have demonstrated associations between declines in PSA screening and concomitant increases in advanced prostate cancer at diagnosis. A retrospective study conducted by Jennifer Cullen, MPH, PhD, was designed to ... Read More »

Testosterone Therapy May Reduce Incidence and Severity of Prostate Cancer

Chicago—There are few data available on whether testosterone therapy in men with hypogonadism increases the incidence or severity of prostate cancer. Researchers in Canada found recently that the risk of prostate cancer diagnosis was decreased in men with long-term testosterone therapy [Wallis et al., Lancet Diab Endocrinol 2016;4:498]. German researchers Ahmad Haider, MD, and Karim Sultan Haider, MD, recently conducted ... Read More »

Post Hoc Analysis of COU-AA-301: CTC as Response Criterion

Chicago—Use of RECIST (Response Evaluation Criteria in Solid Tumors) to assess radiographic response in the majority of patients with metastatic castration-resistant prostate cancer (mCRPC) is limited by the lack of measurable disease. Changes in circulating tumor cell (CTC) counts enumerated by Veridex CellSearch from “unfavorable” at baseline (≥5 cells/7.5 mL) to “favorable” (≤4 cells/7.5 mL) are prognostic for survival. The ... Read More »

Comparing the Rate of Pneumonitis Associated with Treatment with PD-1 and PD-L1 Inhibitors in Patients with Lung Cancer

Chicago—Treatment with the PD-1 and PD-L1 immune checkpoint inhibitors has been shown to be effective in patients with non-small cell lung cancer (NSCLC). However, treatment with these immunotherapy agents has also been associated with potentially fatal immune-related pneumonitis.   To determine if pneumonitis was more frequently associated with one form of treatment, Monica Khunger, MD, and colleagues at the Cleveland ... Read More »

Neutropenia Risk in Patients with Breast Cancer Treated with Palbociclib

Chicago—The cyclin-dependent kinase-4 and -6 inhibitor palbociclib improves progression-free survival in patients with estrogen receptor-positive, metastatic breast cancer (and potentially in other forms of cancer, as well). However, treatment with palbociclib is also associated with severe neutropenia (grade 3 or 4), which can affect treatment adherence and overall outcomes.   To better understand the overall risk of palbociclib-associated neutropenia, Yan ... Read More »